The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have progressed on or after standard therapy and are ineligible for surgical resection or local therapies. 3. Must have measurable disease according to RECIST 1.1. 4. Locally advanced or metastatic disease which is not amenable to curative therapy and has progressed on or is intolerant to standard available therapy as deemed by the investigator. 5. There must be resolution of all systemic treatment-related adverse events. At least 14 days must have elapsed since the last systemic or radiotherapy treatment before screening visit. 6. Documented progressive disease confirmed by either CT (chest and abdomen), MRI or PET/CT scan since patient's last cancer therapy. 7. No prior history of brain metastasis confirmed by CT or MRI within 30 days prior to treatment. 8. Treatment planning CT scan performed within 14 days prior to study treatment. 9. Age ≥18 years. 10. Rib cage circumference ≤ 90 cm. 11. Eastern Cooperative Oncology Group (ECOG) performance status ≤2. 12. Patients should have sufficient organ and bone marrow function on screening day and on procedure day as defined below: Leukocytes ≥3,000/mcL Absolute neutrophil count ≥1,500/mcL Platelets ≥100,000/mcL Total bilirubin ≤ 2.5 x limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤5 x institutional ULN Creatinine Glomerular filtration rate (GFR) ≥50 ml/min/1.73 m2 for patients with creatinine levels above institutional normal. 13. Ability to provide written informed consent document. 14. Confirmation that patient has no electronic or electronically conductive implants or metals: * Via a review of the CT scan * Metal questionnaire filled in by patients Exclusion Criteria: 1. Received chemotherapy, radiotherapy or hormonal therapy within 14 days (before screening). 2. Received immunotherapy/biological therapy or any other investigational agent in the last 21 days (before screening). 3. Not yet recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1). 4. Presence of brain metastases or prior history of brain metastases (if no prior history, confirmed by CT or MRI within 30 days prior to treatment). 5. Known history of allergic reactions attributed to compounds of similar chemical or biological composition (For example: PEG 20,000 Dalton). 6. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, ischemia, or psychiatric illness) that in the opinion of the investigator would either limit compliance with study requirements or put participant at risk. 7. Pregnant and/or breastfeeding. 8. Unwilling to be abstinent or on contraception for up to 30 days after the last study treatment. 9. Presence of electronic or electronically conductive implants or metals in body (verified by screening CT and metal questionnaire). 10. Rib cage circumference over 90 cm. 11. Unable to provide written informed consent. 12. Unable to lay down with hands extended over head.